Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study

Not Applicable

Recruiting

• Conditions: Head and Neck Squamous Cell Carcinoma
• Interventions: Drug: 18-F FDG

• Registration Number: NCT02678884
• Lead Sponsor: University Health Network, Toronto

Brief Summary

The purpose of this study is to see how useful the information provided from Positron Emission Tomography (PET) scans can be in the actual planning and delivery of radiation treatment to patients who have head and neck cancers. Patients participating in this study, will have (in addition to their routine tests) a PET scan before and during their radiation treatment. Following the intervention, patients will be followed as per standard practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-10
• Study First Submitted: 2014-11-27
• Study First Submitted QC: 2016-02-05
• Study First Posted: 2016-02-10
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-12
• Last Update Posted: 2024-03-13
• Primary Completion: 2028-11
• Study Completion: 2028-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Non-nasopharynx head and neck mucosal squamous cell carcinoma
• Radiologically evident gross disease
• Radiotherapy alone for curative intent
• Age equal to or more than 18 years old
• To be eligible for the second study PET-CT scan: FDG avid tumour (or minimum SUV of 2.5) on the first study PET-CT scan

Exclusion Criteria

• Nasopharynx cancer
• H&N SCC skin
• Distant metastases (already known or if found on baseline CT-thorax)
• Prior malignancy within the last 5 years (exclude non-H&N SCC, BCC skin)
• Prior chemotherapy within the last 5 years or concurrent chemotherapy/EGFR inhibitors
• Prior head and neck radiotherapy
• Inability to lie supine for study duration
• Pregnancy
• Inability to provide informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
HNSCC Patients receiving RT	18-F FDG	-

Primary Outcome Measures

Name	Time	Method
Measure rate constant of 18F-FDG uptake in tumour and normal tissue with dynamic PET scanning before radiotherapy.	~ 2 years

Secondary Outcome Measures

Name	Time	Method
Measure rate constant of 18F-FDG uptake in tumour and inflammatory tissue with dynamic PET scanning during radiotherapy .	~ 2 years

Trial Locations

Locations (1)

University Health Network, Princess Margaret Cancer Center; 🇨🇦 Toronto, Ontario, Canada